Citalopram in PMS patients with prior SSRI treatment failure: A preliminary study

Journal of Women's Health

Volumn 11, Issue 5, 2002, Pages 459-464

  Freeman, Ellen W ^a   Jabara, S ^a   Sondheimer, Steven J ^a   Auletto, Roxellen ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

APPETITE; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; HUMAN; LUTEAL PHASE; MOOD; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REMISSION; SYMPTOMATOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME; ADOLESCENT; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; PATIENT SATISFACTION; PROBABILITY;

ADOLESCENT; ADULT; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; PROBABILITY; SEROTONIN UPTAKE INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036597591     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/15246090260137635     Document Type: Article

References (27)

1. Angst J, Sellaro R, Merikangas KR, et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001;104:110.
2. Ramcharan S, Love E, Fick G, et al. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: Attributable risk and risk factors. J Clin Epidemiol 1992;45:377.
3. Logue CM, Moos RH. Perimenstrual symptoms: Prevalence and risk factors. Psychosom Med 1986;48:388.
4. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999;8:122.
5. Endicott J, Amsterdam J, Eriksson E, et al. Is pre-menstrual dysphoric disorder a distinct clinical entity? J Wom Health Gender-Based Med 1999;8:663.
6. Yonkers KA, Clark RH, Trivedi MH. The psychopharmacological treatment of nonmajor mood disorders. Mod Probl Pharmacopsychiatry 1997;25:146.
7. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review. Lancet 2000;356:1131.
8. Halbreich U, Bergeron R, Freeman E, et al. Intermittent luteal phase dosing of sertraline effective in PMDD. Int J Neuropsychopharmacol 2000;3:S249.
9. Judge R, Brown E, Miner C, et al. Intermittent fluoxetine dosing in premenstrual dysphoric disorder. Arch Wom Ment Health 2001;3/4:37.
10. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999;8:328.
11. Freeman EW, Rickels K, Arredondo F, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999;19:3.
12. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997;58:399.
13. Steiner M, Korzekwa M, Lamont J, et al. Intermittent fluoxetine dosing in the treatment of women with pre-menstrual dysphoria. Psychopharmacol Bull 1997;33:771.
14. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18:390.
15. Sunblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo-controlled trial. Neuropsychopharmacology 1993;9:133.
16. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996;65:97.
17. Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992;49:624.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56.
19. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: Superintendent of Documents, U.S. Government Printing Office, U.S. Department of Health, Education, and Welfare Publication No. 76-338; 1976.
20. Norton JW. Citalopram inpatients with SSRI-induced sexual dysfunction. Primary Psychiatry 2000;7:78.
21. Markowitz JS, DeVane CL, Liston HL, et al. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000;15:329.
22. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16.
23. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995;56:30.
24. Thase ME, Ferguson J, Wilcox C. Citalopram treatment of paroxetine intolerant patients. Presented at the New Clinical Drug Evaluation meeting, Boca Raton, FL, 1999.
25. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group [see Comments]. N Engl J Med 1995;332:1529.
26. Diegoli MS, da Fonseca AM, Diegoli CA, et al. A double-blind trial of four medications to treat severe pre-menstrual syndrome. Int J Gynaecol Obstet 1998;62:63.
27. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group [see Comments]. JAMA 1997;278:983.